WARSAW, Ind., June 22, 2020 /PRNewswire/ -- Zimmer Biomet
Holdings, Inc. (NYSE and SIX: ZBH), a global leader in
musculoskeletal healthcare, today announced new features of
mymobility with Apple Watch, creating a first-of-its-kind remote
care management system. These new features expand upon the existing
work between Apple and Zimmer Biomet, who together launched the
mymobility care management system in October
2018 to transform the pre- and post-operative joint
replacement experience.
Experience the interactive Multichannel News Release
here:
https://www.multivu.com/players/English/8739251-zimmer-biomet-mymobility-wwdc-2020/
With the addition of new mobility metrics to measure gait
quality, mymobility will provide healthcare professionals with even
more virtual touchpoints and real-time patient information to
enhance their decision-making process, while patients will continue
to receive a connected and customizable experience throughout their
episode of care. Apple is demonstrating these features to
developers during this year's virtual Worldwide Developers
Conference (WWDC), June 22 to 26,
2020.
With the patient's permission, the new gait quality metrics
leverage the power of Apple's ecosystem by using sensors in the
Apple Watch and iPhone to passively collect walking speed and
double-support time (period of time when both feet are in
contact with the ground) when walking on flat level surfaces –
without GPS. These gait quality measurement features will be
available to hip and knee joint replacement patients and their
healthcare professionals through the mymobility digital platform
later this year.
"Digital transformation of care has been central to Zimmer
Biomet's ongoing evolution and growth prior to the COVID-19
pandemic and is even more important now," said Bryan Hanson, President and CEO of Zimmer
Biomet. "Through mymobility with Apple Watch, we are providing
new and effective ways to optimize the patient experience and
mitigate patient issues, without requiring additional in-office
visits."
mymobility's new gait quality metrics from Apple Watch enable
healthcare professionals to compare their patients' progress
against a database to better manage post-operative care and
potentially identify issues. These new metrics will also be added
to Zimmer Biomet's OrthoIntel Orthopedic Intelligence Platform
created for the purpose of helping to uncover new clinical insights
for surgeons and their care teams.
"While many patients progress according to the treatment plan
and their goals, this isn't the case for all patients. The gait
tracking features and automated check-in notifications can help
identify which patients aren't recovering as expected and what
factors might be contributing," said Dr. Andrew Freiberg, Chief Medical Officer of Zimmer
Biomet. "This real-time data sharing and new gait measurement
feature help provide care teams with more oversight and guidance
related to their patients' recovery through a highly engaged and
connected joint replacement experience."
To learn more about mymobility with Apple Watch, visit
https://www.zimmerbiomet.com/medical-professionals/zb-connect/mymobility.html
About mymobility®
The mymobility digital platform is a care management system on a
patient's wrist that uses iPhone and Apple Watch to facilitate a
new level of connection between patients and their surgical care
teams. By collecting and monitoring objective data about patients'
surgical preparation and recovery, mymobility with Apple Watch
helps surgeons deliver better support and guidance to their
patients throughout their surgical journey.
About OrthoIntel Orthopedic Intelligence
Platform
The OrthoIntel Orthopedic Intelligence Platform connects the
pre-, intra- and post-operative data gathered through the
mymobility digital platform and ROSA® Knee
System to help uncover new clinical insights throughout the
episode of care. These insights are intended to help surgeons and
care teams make informed decisions and improve care.
About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in
musculoskeletal healthcare. We design, manufacture and market
orthopedic reconstructive products; sports medicine, biologics,
extremities and trauma products; office-based technologies; spine,
craniomaxillofacial and thoracic products; dental implants; and
related surgical products.
We collaborate with healthcare professionals around the globe to
advance the pace of innovation. Our products and solutions help
treat patients suffering from disorders of, or injuries to, bones,
joints or supporting soft tissues. Together with healthcare
professionals, we help millions of people live better lives.
We have operations in more than 25 countries around the world
and sell products in more than 100 countries. For more information,
visit www.zimmerbiomet.com or follow Zimmer Biomet on
Twitter at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking
Statements
This news release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements
include, but are not limited to, statements concerning Zimmer
Biomet's expectations, plans, prospects, and product and service
offerings, including new product launches and potential clinical
successes. Such statements are based upon the current beliefs
and expectations of management and are subject to significant
risks, uncertainties and changes in circumstances that could cause
actual outcomes and results to differ materially. For a list
and description of some of such risks and uncertainties, see Zimmer
Biomet's periodic reports filed with the U.S. Securities and
Exchange Commission (SEC). These factors should not be
construed as exhaustive and should be read in conjunction with the
other cautionary statements that are included in Zimmer Biomet's
filings with the SEC. Forward-looking statements speak only
as of the date they are made, and Zimmer Biomet disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise. Readers of this news release are cautioned not
to rely on these forward-looking statements, since there can be no
assurance that these forward-looking statements will prove to be
accurate. This cautionary statement is applicable to all
forward-looking statements contained in this news release.
ZBH-Corp
View original
content:http://www.prnewswire.com/news-releases/new-digital-health-innovations-to-zimmer-biomet-mymobility-aim-to-transform-and-enhance-joint-replacement-standard-of-care-301081307.html
SOURCE Zimmer Biomet